Silver Book Fact

Over the past 15 years, three classes of drugs have reduced mortality and improved symptoms of heart failure in patients who have decreased heart muscle function. These classes of drugs are ACE inhibitors, beta adrenergic blocking agents, and aldosterone antagonists. They each decrease mortality per year by 10-40%, and the beneficial effects of each agent have appeared in large-scale clinical trials to be additive.

Weisfeldt M, Zeiman S. Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease. Health Aff. 2007; 26(1): 25-37. http://content.healthaffairs.org/cgi/content/full/26/1/25

Reference

Title
Advances in the Prevention and Treatment of Cardiovascular Disease: One of the most important contributors to improved human survival is the treatment of cardiovascular disease
Publication
Health Aff
Publication Date
2007
Authors
Weisfeldt M, Zeiman S
Volume & Issue
Volume 26, Issue 1
Pages
25-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Anti-platelet therapy stroke risk reduction
    Anti-platelet therapy after a stroke or TIA reduces the risk of nonfatal ischemic strokes by 28% and fatal strokes by 16%.  
  • Between 1984 and 1998, the cost of treating heart attack patients rose $10,000. However, medical technology increased the life expectancy of heart attack patients by an average of 1 year-a…  
  • Compared to predicted levels in the absence of drug therapy, there were 9% fewer deaths from major cardiovascular disease in 2001 and 38% and 25% fewer hospital discharges for stroke…  
  • The rate of hospitalization from heart failure before and after transcatheter mitral valve repair (TMVR) decreases 73% (per patient year) in patients at prohibitive surgical risk.